Auditory HallucinationsNCT02240446
Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients
A study testing Active tDCS in people with Auditory Hallucinations and Schizophrenia, run by University of Minnesota at 1 site in United States.
Trial summary
The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel neuromodulation approaches using transcranial direct current stimulation (tDCS) for treating schizophrenia patients with medication-resistant auditory… Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Auditory Hallucinations, Schizophrenia
- What is being tested?
- Active tDCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Jun 2013to Dec 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Current DSM-V-defined diagnosis of SZ or Schizoaffective Disorder as assessed by the Structured Clinical Interview for Axis I DSM-V Disorders (SCID-I/P)
- Ages 18-45
- Competent and willing to sign consent form
Who cannot join
- Any serious neurological or endocrine disorder or any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness of more than 30 min, HIV)
- Diagnostic and Statistics Manual (DSM-V) criteria for mental retardation or axis I psychiatric disorder, subjects may have a lifetime but not current diagnosis of depression
- Primary current substance use disorder diagnosis on any substance except for caffeine or nicotine - nicotine use will be recorded but will not be an exclusion criterion
- Medical condition which requires treatment with a medication with psychotropic effects
- Significant risk of suicidal or homicidal behavior
- Documented loss of consciousness (LOC) for longer than 30 minutes or LOC with neurological sequelae
- History of electro-convulsive therapy
- Pregnancy
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Minnesota
Minneapolis, Minnesota, 55414
About this study
Official title: Non-Invasive Brain Stimulation for Clinical Intervention for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients
The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel neuromodulation approaches using transcranial direct current stimulation (tDCS) for treating schizophrenia patients with medication-resistant auditory hallucinations. The investigators will use tDCS to stimulate prefrontal cortex. TDCS is a non-invasive brain stimulation technique that can modulate brain connectivity. Non-invasive brain neuromodulation will be combined (paired-neuromodulation) with training of a task that requires top-down control of auditory processes. Paired-neuromodulation can potentially be used as a therapeutic intervention to decrease auditory hallucinations in schizophrenia.
Read the detailed description
25% of schizophrenia (SZ) patients report chronic auditory hallucinations (AH) despite being on medication. Previous research proposed that hyperactivity of the left temporo-parietal cortex (11) and hypoactivity in left dorsolateral prefrontal cortex (DLPFC) (12) are associated with the onset of AH. While temporal cortex hyperactivity has been extensively manipulated with neuromodulation interventions trying to reduce AH, results have not been consistent (1,13). Recent transcranial direct current stimulation (tDCS) work that targeted both regions above by applying excitatory stimulation over the left DLPFC and inhibitory stimulation on the left temporo-parietal cortex reported a 30% reduction in AH in patients with medication refractory AH that lasted up to 3 months after treatment (14). The investigators are interested to further investigate whether the use of paired neuromodulation (P-NM) with tDCS in co-targeting top-down executive control with bottom-up sensory processes would result in a larger reduction in AH. To date, there are no studies that have used P-NM to examine the magnitude of plasticity of executive control on sensory processing in SZ patients. This type of P-NM would be relevant since AH are thought to be the result of a lack of top-down control over perceptual distortions of internally generated speech. In the forced-attention dichotic listening task (DL), two different syllables are simultaneously presented to the left and the right ear. Subjects are required to pay attention to and report either the left or right ear stimulus. Due to the preponderance of the contralateral pathways, the right ear syllable is projected to the left temporal lobe for processing, while the left ear stimulus is projected to the right temporal lobe and has to be transferred across the corpus callosum to be processed in the left hemisphere. Healthy controls show a right ear advantage (REA) while SZ patients do not (15). DL task performance requires top-down control over auditory cortex and has been associated with increased DLPFC activation in controls (16). Worse performance in this task has been associated with greater severity of AH (17).
SPECIFIC AIMS: The overall aim is to examine the efficacy of tDCS intervention combined with sensory gating training (paired neuro-modulation; P-NM) to reduce hallucinations (as measured by Positive and Negative Syndrome Scale and the Auditory Hallucination Rating Scale). The investigators will collect pilot data to explore the magnitude of DLPFC plasticity during executive control on auditory processing using P-NM and its effect on hallucination-related behavior. The investigators will combine tDCS to enhance left DLPFC activity with auditory stimuli presented to the right ear. The investigators will use the DL task to assess plasticity of top-down control over auditory sensory perception before and after intervention. The investigators will correlate DL task performance to the magnitude of left DLPFC plasticity and with AH severity.
The investigators hypothesize that (a) DLPFC enhancement will facilitate REA in SZ patients by supporting inhibition of attention to irrelevant syllable and facilitating attention to the right ear syllable; (b) continued pairing of left DLPFC activity and auditory processing will reduce auditory hallucinations (as measured by Positive and Negative Syndrome Scale and the Auditory Hallucination Rating Scale).
Methods: The investigators will recruit 50 SZ patients with persistent severe AH despite medication as measured by the Positive and Negative Syndrome Scale and the Auditory Hallucination Rating Scale (AHRS). To examine the effects of P-NM over time, patients will receive transcranial direct current stimulation (tDCS) during five days, twice a day while they practice the dichotic listening task (DL; Hugdahl 2013). During the DL task, patients will be presented with consonant-vowel syllables via headphones. The syllables will consist of paired presentations of the six stop-consonants /b/, /d/, /g/, /p/, /t/, and /k/ together with the vowel /a/ to form dichotic consonant-vowel syllable pairs of the type /ba - ga/,/ta - ka/ etc. The syllables were paired with each other for all possible combinations, thus yielding 36 dichotic pairs, including the homonymic pairs. Patients will be given two different instructions. In one instruction condition they will be told to focus attention to and report from the right ear, and if think they hear something in the left ear, this should be ignored ("forced-right" condition). In the other condition, patients will be asked to focus attention to and report from the left ear, and if they think that they hear something in the right ear, this should be ignored ("forced-left" condition).
Participants will receive either active tDCS treatment or sham stimulation while performing the DL task. Half of them (n=25) will receive either (a) electrical stimulation (2mA) for 20 minutes to the left DLPFC to enhance top-down control and improve the tuning or gating of the extraneous information or (b) while the other half will receive sham stimulation to control for placebo effects. Active tDCS and sham tDCS will be performed with the same tDCS equipment. The difference is that while active tDCS will be configured to reach constant 2mA stimulation for 20 minutes, sham tDCS will be a very brief 2mA stimulation for 30 seconds. During sham tDCS the subject believes he/she is being stimulated normally, but there should not be any real effects. This same procedure will be repeated during five days, twice a day. At the end of day 5 all patients will complete the Positive and Negative Syndrome Scale and the AHRS to evaluate change in AH. Patients will be asked to complete these scales 3, 6, and 9 months after tDCS intervention to examine long-term effects.
- Conditions
- Auditory Hallucinations, Schizophrenia
- Being tested
- Active tDCS, Sham tDCS
- Medical subject headings
- Hallucinations, Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active tDCSDevice
2mA stimulation for 20 minutes twice a day for five consecutive days
Sham tDCSDevice
2mA for 30 seconds twice a day for five consecutive days
| Study group | Role | What they receive |
|---|---|---|
| Active tDCS | Experimental | Active tDCS Receives: Device: Active tDCS |
| Sham tDCS | Placebo comparator | Sham tDCS Receives: Device: Sham tDCS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Positive and Negative Syndrome Scale
Scores from this scale will show severity of auditory hallucinations. We will assess CHANGE in scores between each time-point described in the Time Frame.
Measured: pre-intervention, post-intervention (after five consecutive days of tDCS intervention), 3,6, and 9 months after post-intervention
Secondary outcomes (1)
Auditory Hallucination Rating Scale
Depicts severity of auditory hallucination. We will assess CHANGE in scores between each time-point described in the Time Frame.
Measured: pre-intervention, post-intervention (after five consecutive days of tDCS intervention), 3, 6, and 9 months after post-intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2014 (estimated)
- Study startJun 2013
- Primary completionDec 2017 (estimated)
- Study completionDec 2018 (estimated)
Why it stopped: Will no longer be conducted. We have started a different project.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Auditory HallucinationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jazmin Camchong, PhD, Principal investigator, University of MinnesotaKelvin O Lim, MD, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02240446
- Sponsor's protocol ID
- 1406M51762
- Other IDs
- IEM
- Status last verified
- Jul 2016
- First submitted
- 9 Sep 2014
- Last updated
- 20 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091.
PubMed 22581236Hugdahl K, Nygard M, Falkenberg LE, Kompus K, Westerhausen R, Kroken R, Johnsen E, Loberg EM. Failure of attention focus and cognitive control in schizophrenia patients with auditory verbal hallucinations: evidence from dichotic listening. Schizophr Res. 2013 Jul;147(2-3):301-9. doi: 10.1016/j.schres.2013.04.005. Epub 2013 May 9.
PubMed 23664588Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry. 2002 Jun 15;51(12):1008-11. doi: 10.1016/s0006-3223(02)01316-1.
PubMed 12062886Thomsen T, Rimol LM, Ersland L, Hugdahl K. Dichotic listening reveals functional specificity in prefrontal cortex: an fMRI study. Neuroimage. 2004 Jan;21(1):211-8. doi: 10.1016/j.neuroimage.2003.08.039.
PubMed 14741658
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Non-Invasive Brain Stimulation for Clinical Intervention for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients
- ClinicalTrials.gov ID
- NCT02240446
- Acronym / sponsor ID
- 1406M51762
- Conditions
- Auditory Hallucinations, Schizophrenia
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Will no longer be conducted. We have started a different project.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- Jun 2013
- Primary completion
- Dec 2017 (estimated)
- Study completion
- Dec 2018 (estimated)
- First posted
- 15 Sep 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching goal of this project is to expand the traditional expertise in non-invasive neuromodulation at the University of Minnesota towards developing novel neuromodulation approaches using transcranial direct current stimulation (tDCS) for treating schizophrenia patients with medication-resistant auditory hallucinations. The investigators will use tDCS to stimulate prefrontal cortex. TDCS is a non-invasive brain stimulation technique that can modulate brain connectivity. Non-invasive brain neuromodulation will be combined (paired-neuromodulation) with training of a task that requires top-down control of auditory processes. Paired-neuromodulation can potentially be used as a therapeutic intervention to decrease auditory hallucinations in schizophrenia.
Detailed description
25% of schizophrenia (SZ) patients report chronic auditory hallucinations (AH) despite being on medication. Previous research proposed that hyperactivity of the left temporo-parietal cortex (11) and hypoactivity in left dorsolateral prefrontal cortex (DLPFC) (12) are associated with the onset of AH. While temporal cortex hyperactivity has been extensively manipulated with neuromodulation interventions trying to reduce AH, results have not been consistent (1,13). Recent transcranial direct current stimulation (tDCS) work that targeted both regions above by applying excitatory stimulation over the left DLPFC and inhibitory stimulation on the left temporo-parietal cortex reported a 30% reduction in AH in patients with medication refractory AH that lasted up to 3 months after treatment (14). The investigators are interested to further investigate whether the use of paired neuromodulation (P-NM) with tDCS in co-targeting top-down executive control with bottom-up sensory processes would result in a larger reduction in AH. To date, there are no studies that have used P-NM to examine the magnitude of plasticity of executive control on sensory processing in SZ patients. This type of P-NM would be relevant since AH are thought to be the result of a lack of top-down control over perceptual distortions of internally generated speech. In the forced-attention dichotic listening task (DL), two different syllables are simultaneously presented to the left and the right ear. Subjects are required to pay attention to and report either the left or right ear stimulus. Due to the preponderance of the contralateral pathways, the right ear syllable is projected to the left temporal lobe for processing, while the left ear stimulus is projected to the right temporal lobe and has to be transferred across the corpus callosum to be processed in the left hemisphere. Healthy controls show a right ear advantage (REA) while SZ patients do not (15). DL task performance requires top-down control over auditory cortex and has been associated with increased DLPFC activation in controls (16). Worse performance in this task has been associated with greater severity of AH (17).
SPECIFIC AIMS: The overall aim is to examine the efficacy of tDCS intervention combined with sensory gating training (paired neuro-modulation; P-NM) to reduce hallucinations (as measured by Positive and Negative Syndrome Scale and the Auditory Hallucination Rating Scale). The investigators will collect pilot data to explore the magnitude of DLPFC plasticity during executive control on auditory processing using P-NM and its effect on hallucination-related behavior. The investigators will combine tDCS to enhance left DLPFC activity with auditory stimuli presented to the right ear. The investigators will use the DL task to assess plasticity of top-down control over auditory sensory perception before and after intervention. The investigators will correlate DL task performance to the magnitude of left DLPFC plasticity and with AH severity.
The investigators hypothesize that (a) DLPFC enhancement will facilitate REA in SZ patients by supporting inhibition of attention to irrelevant syllable and facilitating attention to the right ear syllable; (b) continued pairing of left DLPFC activity and auditory processing will reduce auditory hallucinations (as measured by Positive and Negative Syndrome Scale and the Auditory Hallucination Rating Scale).
Methods: The investigators will recruit 50 SZ patients with persistent severe AH despite medication as measured by the Positive and Negative Syndrome Scale and the Auditory Hallucination Rating Scale (AHRS). To examine the effects of P-NM over time, patients will receive transcranial direct current stimulation (tDCS) during five days, twice a day while they practice the dichotic listening task (DL; Hugdahl 2013). During the DL task, patients will be presented with consonant-vowel syllables via headphones. The syllables will consist of paired presentations of the six stop-consonants /b/, /d/, /g/, /p/, /t/, and /k/ together with the vowel /a/ to form dichotic consonant-vowel syllable pairs of the type /ba - ga/,/ta - ka/ etc. The syllables were paired with each other for all possible combinations, thus yielding 36 dichotic pairs, including the homonymic pairs. Patients will be given two different instructions. In one instruction condition they will be told to focus attention to and report from the right ear, and if think they hear something in the left ear, this should be ignored ("forced-right" condition). In the other condition, patients will be asked to focus attention to and report from the left ear, and if they think that they hear something in the right ear, this should be ignored ("forced-left" condition).
Participants will receive either active tDCS treatment or sham stimulation while performing the DL task. Half of them (n=25) will receive either (a) electrical stimulation (2mA) for 20 minutes to the left DLPFC to enhance top-down control and improve the tuning or gating of the extraneous information or (b) while the other half will receive sham stimulation to control for placebo effects. Active tDCS and sham tDCS will be performed with the same tDCS equipment. The difference is that while active tDCS will be configured to reach constant 2mA stimulation for 20 minutes, sham tDCS will be a very brief 2mA stimulation for 30 seconds. During sham tDCS the subject believes he/she is being stimulated normally, but there should not be any real effects. This same procedure will be repeated during five days, twice a day. At the end of day 5 all patients will complete the Positive and Negative Syndrome Scale and the AHRS to evaluate change in AH. Patients will be asked to complete these scales 3, 6, and 9 months after tDCS intervention to examine long-term effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active tDCS | Experimental | Device: Active tDCSActive tDCS |
| Sham tDCS | Placebo comparator | Device: Sham tDCSSham tDCS |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Current DSM-V-defined diagnosis of SZ or Schizoaffective Disorder as assessed by the Structured Clinical Interview for Axis I DSM-V Disorders (SCID-I/P)
- Ages 18-45
- Competent and willing to sign consent form
Key exclusion criteria (8 listed)
- Any serious neurological or endocrine disorder or any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, loss of consciousness of more than 30 min, HIV)
- Diagnostic and Statistics Manual (DSM-V) criteria for mental retardation or axis I psychiatric disorder, subjects may have a lifetime but not current diagnosis of depression
- Primary current substance use disorder diagnosis on any substance except for caffeine or nicotine - nicotine use will be recorded but will not be an exclusion criterion
- Medical condition which requires treatment with a medication with psychotropic effects
- Significant risk of suicidal or homicidal behavior
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active tDCS2mA stimulation for 20 minutes twice a day for five consecutive days | Device | Active tDCS |
| Sham tDCS2mA for 30 seconds twice a day for five consecutive days | Device | Sham tDCS |
Primary outcome
Positive and Negative Syndrome Scale
Time frame: pre-intervention, post-intervention (after five consecutive days of tDCS intervention), 3,6, and 9 months after post-intervention
Scores from this scale will show severity of auditory hallucinations. We will assess CHANGE in scores between each time-point described in the Time Frame.
1 secondary outcome
Auditory Hallucination Rating Scale
Time frame: pre-intervention, post-intervention (after five consecutive days of tDCS intervention), 3, 6, and 9 months after post-intervention
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2016.
- Background: PubMed 22581236Brunelin J, Mondino M, Gassab L, Haesebaert F, Gaha L, Suaud-Chagny MF, Saoud M, Mechri A, Poulet E. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. Am J Psychiatry. 2012 Jul;169(7):719-24. doi: 10.1176/appi.ajp.2012.11071091.
- Background: PubMed 23664588Hugdahl K, Nygard M, Falkenberg LE, Kompus K, Westerhausen R, Kroken R, Johnsen E, Loberg EM. Failure of attention focus and cognitive control in schizophrenia patients with auditory verbal hallucinations: evidence from dichotic listening. Schizophr Res. 2013 Jul;147(2-3):301-9. doi: 10.1016/j.schres.2013.04.005. Epub 2013 May 9.
- Background: PubMed 12062886Lawrie SM, Buechel C, Whalley HC, Frith CD, Friston KJ, Johnstone EC. Reduced frontotemporal functional connectivity in schizophrenia associated with auditory hallucinations. Biol Psychiatry. 2002 Jun 15;51(12):1008-11. doi: 10.1016/s0006-3223(02)01316-1.
- Background: PubMed 14741658Thomsen T, Rimol LM, Ersland L, Hugdahl K. Dichotic listening reveals functional specificity in prefrontal cortex: an fMRI study. Neuroimage. 2004 Jan;21(1):211-8. doi: 10.1016/j.neuroimage.2003.08.039.
Related trials for Auditory Hallucinations
Recruiting
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
Auditory Verbal Hallucinations, Schizophrenia
Recruiting
Neuronavigated rTMS for Treatment-Resistant Auditory Hallucinations
Schizophrenia, Auditory Verbal Hallucinations
Recruiting
fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations
Schizophrenia, Hallucinations, Auditory
Recruiting
Impact of EDEN College Courses on the Quality of Life of Voice-Hearers
Hallucinations, Auditory
Not yet recruiting
LIFU Effects & Outcomes: Mechanisms Evaluating Striatal Systems Imaging (LEO MESSI)
Schizophrenia, Auditory Hallucinations
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jazmin Camchong, PhD principal investigator
University of Minnesota
Kelvin O Lim, MD principal investigator
University of Minnesota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active tDCS in people with Auditory Hallucinations and Schizophrenia, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 20 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Positive and Negative Syndrome Scale (time frame: pre-intervention, post-intervention (after five consecutive days of tDCS intervention), 3,6, and 9 months after post-intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02240446, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2016; AzTrials last refreshed its copy on 31 Oct 2026.